Opinion: STAT+: How the FDA and CMS worked together on a new approach to...
The United States continues to face a pervasive public health challenge: lack of access to behavioral health providers and resources. Behavioral health conditions have been significantly increasing in...
View ArticleOpinion: STAT+: We need a universal approach to sharing biomedical samples
Three years ago, I was working at a biotech company leading a drug discovery program focused on metabolic disease. Interested in obtaining liver samples that could help identify potential therapeutic...
View ArticleOpinion: STAT+: The life sciences industry needs a new approach
The life sciences industry is experiencing an identity crisis. Despite great scientific innovation in the past decade and the highest per capita expenditure on health care in the world, U.S. patients...
View ArticleOpinion: STAT+: The travel industry offers hospitals a warning about MyChart
A few decades ago, hotels were supreme. They had strong relationships with their customers, who were deeply loyal to particular hotels they trusted. But that has changed with the rise of online travel...
View ArticleOpinion: STAT+: Recursion CEO: Publicly funded research built the biopharma...
America is the global leader in health care innovation. We lead in medical research and in rapidly developing treatments for emerging health care priorities. That leadership isn’t free. But it isn’t...
View ArticleOpinion: STAT+: There’s a better way to get drugs on the market: progressive...
The public and pharmaceutical companies are calling for changes in drug regulation and the costs of medicines. They are right to do so. Companies want to see products approved faster for financial...
View ArticleOpinion: STAT+: Why AI like Grok isn’t ready for the radiology big leagues
Recently, a bunch of people at my local basketball club watched me swagger onto a court and sink a 35-footer. Nothing but net. I soaked in the adulation and gave the requisite high-fives. What I did...
View ArticleOpinion: STAT+: Volatile is the new normal for the biotech workforce
In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 million...
View ArticleOpinion: STAT+: How will the Center for Biologics Evaluation and Research...
Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler. With all the uncertainties surrounding the Food and Drug Administration under Trump 2.0, the recent agency...
View ArticleOpinion: STAT+: The women’s health sector is on the verge of a pivotal...
Women’s health is finally receiving the attention it deserves from the venture capital world. Over the past five years, investments in startups in the women’s health space have surged to unprecedented...
View ArticleOpinion: STAT+: RFK Jr.’s regenerative medicine roundtable on stem cell...
Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler. Health and Human Services Secretary Robert F. Kennedy Jr. held a regenerative medicine roundtable on March...
View ArticleOpinion: HIPAA can’t keep up with health care’s security crisis
The health care industry faces a critical security challenge. While organizations invest millions in advanced medical technologies, their approach to protecting sensitive data remains notably outdated....
View ArticleOpinion: STAT+: Philanthropy can help create a healthier biotech ecosystem
Small, early-stage biotech startups are the heart of drug innovation in the U.S. Growing anti-competitive challenges threaten their work, but philanthropy may offer an avenue forward. At the center of...
View ArticleOpinion: STAT+: Impatient about cell and gene therapy? Progress in biotech is...
The sale of bluebird bio and Pfizer’s decision to drop a gene therapy for hemophilia have led to some anxiety regarding the future of cell and gene therapy (CGT). As the chief executive officer of the...
View ArticleOpinion: STAT+: Peter Marks’ ouster is an ominous sign for biotech — and for...
Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler. There are certain leaders who quietly make complex organizations operate well including in the toughest of...
View ArticleOpinion: STAT+: BridgeBio CEO: Congress must renew a popular, bipartisan FDA...
Thousands of children’s lives have been saved by a cost-free government initiative that expired last December. Congress needs to renew this program quickly because too many babies are dying needlessly....
View ArticleOpinion: The Trump administration should rescind the NIH ‘access planning’ rule
At the start of the year, the National Institutes of Health finalized a policy that will require anyone seeking to license certain NIH-owned patents to submit an “access plan” detailing how they plan...
View ArticleOpinion: STAT+: Biotech investors: Stop expecting CRISPR science to make big...
The medical promise of CRISPR gene editing can be seen most easily in current research on oral cancer, which affects more than 50,000 Americans every year. An increasing challenge in the treatment of...
View ArticleOpinion: STAT+: Promising signs for stem cell-based therapies for Parkinson’s...
Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler. I’m upbeat about cell therapy development for Parkinson’s disease, but it has been a marathon. Now two new...
View ArticleOpinion: STAT+: A dangerous new push to ban embryonic stem cell research...
Welcome to Lab Dish, a First Opinion column on regenerative medicine from Paul Knoepfler. Twenty years ago, the use of human embryonic stem cells in research was among the most fiercely debated topics...
View Article